Total Payments
$1,078
2023 Payments
$686.92
Companies
23
Transactions
64
Medicare Patients
1,844
Medicare Billing
$212,427
Payment Breakdown by Category
Food & Beverage$1,067 (99.0%)
Education$10.76 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,067 | 60 | 99.0% |
| Education | $10.76 | 4 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $173.55 | 10 | $0 (2023) |
| PFIZER INC. | $134.81 | 8 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $116.39 | 5 | $0 (2023) |
| Novo Nordisk Inc | $101.91 | 6 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $65.64 | 4 | $0 (2023) |
| Biohaven Pharmaceutical Holding Company Ltd. | $56.97 | 3 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.91 | 2 | $0 (2022) |
| Exact Sciences Corporation | $43.20 | 2 | $0 (2023) |
| IDORSIA PHARMACEUTICALS US INC | $36.42 | 2 | $0 (2023) |
| Lilly USA, LLC | $34.83 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $686.92 | 39 | PFIZER INC. ($124.37) |
| 2022 | $300.00 | 16 | Biohaven Pharmaceutical Holding Company Ltd. ($56.97) |
| 2021 | $69.67 | 4 | AbbVie Inc. ($35.34) |
| 2017 | $21.20 | 5 | Sunovion Pharmaceuticals Inc. ($10.76) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: PAIN | ||||||
| 12/04/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Oncology | ||||||
| 11/30/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: PAIN | ||||||
| 11/09/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: PAIN | ||||||
| 11/06/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: INSOMNIA | ||||||
| 10/12/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/03/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Inflammation | ||||||
| 09/13/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 08/17/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), REXULTI | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: PSYCHIATRY | ||||||
| 08/10/2023 | PFIZER INC. | PAXLOVID (Drug), NURTEC ODT, ZAVZPRET | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 07/18/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $13.71 | General |
| Category: GI | ||||||
| 07/14/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: INSOMNIA | ||||||
| 07/06/2023 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $16.00 | General |
| Category: Opioid Analgesic | ||||||
| 06/16/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Cardio-renal | ||||||
| 06/13/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $12.89 | General |
| Category: Opioid Analgesic | ||||||
| 06/08/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Diabetes | ||||||
| 05/18/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Cardio-renal | ||||||
| 05/08/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: Diabetes | ||||||
| 04/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: PAIN | ||||||
| 04/24/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Iron Deficiency Anemia | ||||||
| 04/13/2023 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 164 | 612 | $106,372 | $44,310 |
| 2022 | 10 | 346 | 1,063 | $162,938 | $77,462 |
| 2021 | 14 | 286 | 539 | $70,820 | $37,566 |
| 2020 | 17 | 1,048 | 2,392 | $247,596 | $53,089 |
Total Patients
1,844
Total Services
4,606
Medicare Billing
$212,427
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 241 | $54,929 | $19,835 | 36.1% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 52 | 253 | $30,360 | $15,355 | 50.6% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 17 | 45 | $9,831 | $4,993 | 50.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 73 | $11,252 | $4,126 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 310 | $69,750 | $27,679 | 39.7% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 76 | 344 | $41,280 | $20,742 | 50.2% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 26 | 70 | $16,940 | $10,914 | 64.4% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 36 | 80 | $14,160 | $8,955 | 63.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 38 | 95 | $12,730 | $5,711 | 44.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $4,920 | $1,932 | 39.3% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2022 | 18 | 58 | $1,160 | $841.41 | 72.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 19 | 38 | $1,406 | $394.43 | 28.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 15 | 34 | $340.00 | $147.20 | 43.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 12 | 14 | $252.00 | $145.84 | 57.9% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 35 | 72 | $17,424 | $11,274 | 64.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 86 | $19,350 | $8,499 | 43.9% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 43 | 100 | $12,000 | $6,160 | 51.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 39 | 67 | $8,978 | $4,630 | 51.6% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 17 | 28 | $4,956 | $3,107 | 62.7% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2021 | 11 | 13 | $1,469 | $975.00 | 66.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 13 | 13 | $2,600 | $925.80 | 35.6% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 13 | 15 | $795.00 | $529.95 | 66.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 41 | $1,517 | $455.50 | 30.0% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2021 | 11 | 13 | $494.00 | $325.00 | 65.8% |
| 99406 | Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes | Office | 2021 | 13 | 20 | $400.00 | $306.80 | 76.7% |
About Dr. David Jaroszewski, MD
Dr. David Jaroszewski, MD is a Pain Medicine healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831136811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Jaroszewski, MD has received a total of $1,078 in payments from pharmaceutical and medical device companies, with $686.92 received in 2023. These payments were reported across 64 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($1,067).
As a Medicare-enrolled provider, Jaroszewski has provided services to 1,844 Medicare beneficiaries, totaling 4,606 services with total Medicare billing of $212,427. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Other Specialties Family Medicine
- Location Winston Salem, NC
- Active Since 05/31/2006
- Last Updated 12/14/2021
- Taxonomy Code 208VP0000X
- Entity Type Individual
- NPI Number 1831136811
Products in Payments
- NURTEC ODT (Drug) $166.35
- UBRELVY (Drug) $93.57
- ABILIFY MAINTENA (Drug) $66.43
- Kerendia (Drug) $65.64
- QULIPTA (Drug) $58.35
- RELISTOR (Drug) $43.91
- Cologuard Collection Kit (Device) $43.20
- QUVIVIQ (Drug) $36.42
- MOUNJARO (Drug) $34.83
- BELSOMRA (Drug) $34.49
- NALOCET (Drug) $34.39
- Wegovy (Drug) $34.25
- Ozempic (Drug) $29.56
- OCALIVA (Drug) $28.73
- REXULTI (Drug) $28.39
- INJECTAFER (Drug) $24.73
- Rybelsus (Drug) $22.27
- VIBERZI (Drug) $21.63
- ABILIFY ASIMTUFII (Drug) $21.57
- SHINGRIX (Biological) $19.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pain Medicine Doctors in Winston Salem
James North, Md, MD
Pain Medicine — Payments: $1.1M
Pain Medicine $1.1M
Leonardo Kapural, M.d, M.D
Pain Medicine — Payments: $1.1M
Pain Medicine $1.1M
Dr. Christopher Gilmore, Md, MD
Pain Medicine — Payments: $548,646
Pain Medicine $548,646
Daniel Bintrim, M.d, M.D
Pain Medicine — Payments: $36,124
Pain Medicine $36,124
Dr. Paul Harkins, Md, MD
Pain Medicine — Payments: $22,233
Pain Medicine $22,233
Chuanyao Tong, Md, MD
Pain Medicine — Payments: $20,759
Pain Medicine $20,759